0000899243-18-025079.txt : 20180924
0000899243-18-025079.hdr.sgml : 20180924
20180924180508
ACCESSION NUMBER: 0000899243-18-025079
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180920
FILED AS OF DATE: 20180924
DATE AS OF CHANGE: 20180924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Morningside Venture Investments Ltd
CENTRAL INDEX KEY: 0001543112
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 181084339
BUSINESS ADDRESS:
STREET 1: MCCARTHY LEGAL SERVICES
STREET 2: 1188 CENTRE STREET
CITY: NEWTON CENTRE
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-244-2800
MAIL ADDRESS:
STREET 1: MCCARTHY LEGAL SERVICES
STREET 2: 1188 CENTRE STREET
CITY: NEWTON CENTRE
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
BUSINESS PHONE: 502-241-4114
MAIL ADDRESS:
STREET 1: 6400 WESTWIND WAY
STREET 2: SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-09-20
0
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001543112
Morningside Venture Investments Ltd
2ND FLOOR, LE PRINCE DE GALLES
3-5 AVENUE DES CITRONNIERS
MC 98000
O9
MONACO
0
0
1
0
Common Stock
2018-09-20
4
P
0
19599
18.79
A
11512902
D
Common Stock
2018-09-20
4
P
0
21724
19.43
A
11534626
D
Common Stock
2018-09-21
4
P
0
40000
19.84
A
11574626
D
The reported price is a weighted average price. These shares were purchased on 9/20/2018 in multiple transactions at prices ranging from $18.25 to $19.24, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were purchased on 9/20/2018 in multiple transactions at prices ranging from $19.25 to $19.60, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price is a weighted average price. These shares were purchased on 9/21/2018 in multiple transactions at prices ranging from $19.48 to $20.14, inclusive. The reporting person undertakes to provide to Apellis Pharmaceuticals, Inc., any security holder of Apellis Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Louise Mary Garbarino, Jill Marie Franklin, Peter Stuart Allenby Edwards and Raymond Long Sing Tang, the directors of Morningside Venture Investments, Ltd. ("MVIL"), share voting and dispositive control over the shares held by MVIL.
/s/ Louise Mary Garbarino
2018-09-24
/s/ Jill Marie Franklin
2018-09-24